Personalis Inc
NASDAQ:PSNL

Watchlist Manager
Personalis Inc Logo
Personalis Inc
NASDAQ:PSNL
Watchlist
Price: 3.47 USD 2.66% Market Closed
Market Cap: 245.2m USD
Have any thoughts about
Personalis Inc?
Write Note

Personalis Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Personalis Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Personalis Inc
NASDAQ:PSNL
Cost of Revenue
-$60m
CAGR 3-Years
-3%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Cost of Revenue
-$25.1B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-11%
Danaher Corp
NYSE:DHR
Cost of Revenue
-$8.6B
CAGR 3-Years
8%
CAGR 5-Years
-4%
CAGR 10-Years
0%
Mettler-Toledo International Inc
NYSE:MTD
Cost of Revenue
-$1.5B
CAGR 3-Years
-1%
CAGR 5-Years
-4%
CAGR 10-Years
-3%
Agilent Technologies Inc
NYSE:A
Cost of Revenue
-$2.9B
CAGR 3-Years
-1%
CAGR 5-Years
-5%
CAGR 10-Years
-11%
IQVIA Holdings Inc
NYSE:IQV
Cost of Revenue
-$9.9B
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
-10%
No Stocks Found

Personalis Inc
Glance View

Market Cap
245.1m USD
Industry
Life Sciences Tools & Services

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company is headquartered in Menlo Park, California and currently employs 325 full-time employees. The company went IPO on 2019-06-20. The firm is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The company provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. The company also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.

PSNL Intrinsic Value
1.91 USD
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Personalis Inc's Cost of Revenue?
Cost of Revenue
-60m USD

Based on the financial report for Sep 30, 2024, Personalis Inc's Cost of Revenue amounts to -60m USD.

What is Personalis Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-9%

Over the last year, the Cost of Revenue growth was -9%. The average annual Cost of Revenue growth rates for Personalis Inc have been -3% over the past three years , -9% over the past five years .

Back to Top